CMRG 2022 Review of the 64th ASH Annual Meeting and Exposition

Thank you for joining CMRG as we discuss highlights from this year's 64th ASH Annual Meeting and Exposition.

Let's connect!

Timestamps
00:00 Dr. Donna Reece- Opening words
01:26 Dr. Arleigh McCurdy- Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed with MM: Abstract 117
07:04 Dr. Michael Sebag- Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible Newly Diagnosed MM: Abstract 3238
15:45 Dr. Chris Venner- Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed MM:Abstract 866
26:15 Dr. Donna Reece - Initial Therapy in Canada-Options and Challenges-Transplant Eligible
40:33 Dr. Julie Stakiw-Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed MM: Abstract 4553
47:16 Dr. Donna Reece-Initial Therapy in Canada-Options and Challenges-Transplant Ineligible
53:30 Dr. Chris Venner- Real World Data on Outcomes of Anti-CD38 Antibody Refractory, incl Triple Class Refractory Patients with MM: Abstract 1867
59:13 Dr. Arleigh McCurdy-Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostomab in Patients with Relapsed/Refractory MM.: Abstract 567
1:02:47 Dr. Darrell White-Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with DEX in Patients with RRMM: Abstract 568
1:08:56 Dr. Donna Reece-Relapsed Refractory Disease-Options and Challenges
1:14:22 Dr. Donna Reece- Final words, event close